Site Search by Google

Resources

Libraries
Human "32k" BAC Re-Array
GENSAT Collection
Vectors
Filters
Filter Interpreter Application
Mapped Clones
Non-Recombinants


Procedures
Online Mapping Resources
Download Page
Questions and Answers

Research

BAC Library Construction
ALS
Publications

 
 Resources 
 Vector pCYPAC2 Information    

We have combined the best features of the P1 and BAC systems.  The pCYPAC2 vector has been constructed for the cloning of large DNA fragments following electroporation.   This vector has been constructed by removing the stuffer fragment form the pAd10SacBII vector (Pierce, J. C., Sauer, B. and Sternberg, N. (1992) Proc. Natl. Acad. Sci, USA 89: 2056-2060.) and inserting a pUC plasmid into the BamHI cloning site.

The pUC sequence has not been inserted in a permanent way.  During the cloning process, pUC sequences are removed through a double-digestion scheme, which employs BamHI and ScaI.  The pUC plasmid cannot back into the BamHI cloning site, which would otherwise result in the creation of non-recombinant background clones in the library.

Re-ligation into the BamHI site is prevented at three levels:

 

1.  pUC has been cleaved into ScaI fragments (ends incompatible with BamHI)
2.  The BamHI/ScaI oligo linkers have been physically separated from the pUC and PAC-vector fragments and
3.  All vector derived fragments have been treated with alkaline phosphates to inhibit ligation of vector-to-vector ends

pCYPAC2 clones have Kanamycin antibiotic resistance.  Clones should be grown in LB containing 25ug Kanamycin/ml.

 

We have replaced the SciI site with a second NotI site to allow release of most inserts as a single large fragment.  This facilitates size determination of inserts as a single large fragment.  This facilitates size determination of inserts and determining the completeness of the NotI digest reaction (via appearance of a constant vector product).


Contact BACPAC Resources ( BACPACorders@chori.org ) for further information regarding current availability or ordering.

For questions related to the site, please contact webmaster.
The use of this website is subject to the terms of use.